Thermo Fisher Scientific (TMO) Common Equity (2009 - 2026)

Thermo Fisher Scientific has reported Common Equity for 18 years, with the latest figure at $52.7 billion in Q2 2026.

• Common Equity for Q2 2026 came in at $52.7 billion, up 4.38% year-over-year; the trailing twelve-month figure through Jun 2026 was $52.7 billion (up 4.38% YoY), and the FY2025 annual result was $53.4 billion, up 7.8% from the prior year.
• Common Equity rose to $52.7 billion in Q2 2026, from $51.9 billion in the prior quarter.
• Over five years, Common Equity peaked at $53.4 billion in Q4 2025 and troughed at $41.0 billion in Q2 2022.
• A 5-year average of $47.2 billion and a median of $47.1 billion in 2023 frame the typical range for Common Equity.
• The widest annual swing landed in 2022, when Common Equity grew 16.97%; it then grew 3.15% in 2023.
• A 5-year view of Common Equity shows it stood at $44.0 billion in 2022, then gained by 6.11% to $46.7 billion in 2023, then rose by 6.05% to $49.6 billion in 2024, then advanced by 7.8% to $53.4 billion in 2025, then dropped by 1.36% to $52.7 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $52.7 billion in Q2 2026, $51.9 billion in Q1 2026, and $53.4 billion in Q4 2025.